Catalent is rapidly scaling up its manufacturing capacity in Bloomington to enable production of a SARS-CoV-2 vaccine candidate that is currently being by developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The collaboration involves joint investment from Catalent and Janssen to enable large-scale commercial manufacturing by January of 2021, with segregated cGMP production lines operating 24/7 to create approximately a billion doses.
Catalent’s 875,000-sf facility in Bloomington has deep expertise in sterile formulation, with drug substance development and manufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges, as well as primary and secondary packaging. The Catalent Biologics network also has locations in Belgium and Italy that support sterile drug product manufacturing and packaging. Additional facilities in the United States and Europe are equipped for the manufacture of proteins, viral vectors for gene therapies, and cell therapies.
Catalent is significantly accelerating the construction timetable of a $112 million, 72,000-sf expansion and renovation project that is already underway in Bloomington to enable production of Janssen's clinical vaccine candidate to begin in July of 2020.
